StreetInsider.com News Articles

Form 144 Veradermics, Inc Filed by: Averill Master Fund, Ltd.

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991472.html

Form 144 Veradermics, Inc Filed by: Averill Madison Master Fund, Ltd.

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991492.html

Form SCHEDULE 13D/A Veradermics, Inc Filed by: MONTANOVA CAPITAL, LLC

Fri, 21 Aug 2026 18:32:00 -0400

si-local-file:///var/storage/secattach/20260821/26962674.html

Form 4 Veradermics, Inc For: Aug 19 Filed by: MONTANOVA CAPITAL, LLC

Fri, 21 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26962651.html

Form 3 Veradermics, Inc For: Aug 10 Filed by: Hollander David

Thu, 20 Aug 2026 19:05:00 -0400

si-local-file:///var/storage/secattach/20260820/26957445.html

Form 144 Veradermics, Inc Filed by: Averill Master Fund, Ltd.

Wed, 19 Aug 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260819/26951536.html

Form 144 Veradermics, Inc Filed by: Averill Madison Master Fund, Ltd.

Wed, 19 Aug 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260819/26951534.html

Form 4 Veradermics, Inc For: Aug 17 Filed by: Durso Timothy August

Tue, 18 Aug 2026 21:10:00 -0400

si-local-file:///var/storage/secattach/20260818/26946074.html

Form 4 Veradermics, Inc For: Aug 17 Filed by: Waldman Reid Alexander

Tue, 18 Aug 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26946065.html

Form 144 Veradermics, Inc Filed by: Durso Timothy August

Mon, 17 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260817/26939064.html

Form 144 Veradermics, Inc Filed by: Waldman Reid Alexander

Mon, 17 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26939029.html

Form EFFECT Veradermics, Inc

Mon, 17 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260817/26934387.html

Form SCHEDULE 13D/A Veradermics, Inc Filed by: SR ONE CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26933254.html

Form 144/A Veradermics, Inc Filed by: CHILDS JOHN W

Fri, 14 Aug 2026 18:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26933151.html

Form 4 Veradermics, Inc For: Aug 12 Filed by: CHILDS JOHN W

Fri, 14 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26933093.html

Form 424B3 Veradermics, Inc

Fri, 14 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26932558.html

Form 144 Veradermics, Inc Filed by: AMZL, LP

Wed, 12 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26914585.html

Form 144 Veradermics, Inc Filed by: SR One Capital Fund II Aggregator, LP

Wed, 12 Aug 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26914582.html

Form 10-Q Veradermics, Inc For: Jun 30

Tue, 11 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260811/26906501.html

Form 8-K Veradermics, Inc For: Aug 11

Tue, 11 Aug 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26901971.html

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Tue, 11 Aug 2026 07:30:00 -0400

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth

Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female pattern hair loss, marking a milestone in the development of the potential first oral prescription treatment for women; topline readout anticipated in 1H27

VDPHL01 has the potential to be the first extended-release oral minoxidil therapy for women and men with pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Tue, 11 Aug 2026 07:30:00 -0400

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth
Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female pattern hair loss, marking a milestone in the development of the potential first oral prescription treatment for women; topline readout anticipated in 1H27
VDPHL01 has the potential to be the first extended-release oral minoxidil therapy for women and men with pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United

Form S-1 Veradermics, Inc

Fri, 07 Aug 2026 17:09:00 -0400
si-local-file:///var/storage/secattach/20260807/26892123.html

Form SCHEDULE 13G Veradermics, Inc Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400
si-local-file:///var/storage/secattach/20260806/26881420.html

Veradermics presents Phase 2/3 hair loss drug data at AAD meeting

Fri, 17 Jul 2026 07:30:24 -0400

Veradermics, Incorporated (NYSE: MANE) presented data from a subgroup analysis of its Phase 2/3 Study '302' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in male patients with mild-to-moderate pattern hair loss, according to a company statement.

The data were shared in a poster presentation on July 16, 2026, and in an oral presentation on July 17, 2026, at the 2026 American Academy of Dermatology Innovation Academy in New York City. The oral presentation was delivered by Maria Hordinsky, MD, FAAD, professor and vice chair of research in the Department of Dermatology at the University of Minnesota Twin Cities.

Study '302' is